Vol 6, No 1 (2019) > Articles >

Improvement of Losartan Transdermal Permeation using Oleic Acid Pretreatment: in Vitro Observation and in Vivo Prediction

Annas Binarjo , Akhmad Kharis Nugroho

 

Abstract:

ABSTRACT

The effect of oleic acid on losartan transdermal permeation has been observed to explore its ability as chemical enhancer. Potassium losartan solutions in citric buffer pH 5.0 were made in two levels of concentration i.e. 2 mg/mL and 10 mg/mL using propylene glycol 15% as solubilizing agent. Losartan transport from such solutions with and without oleic acid one hour pretreatment were tested using male Wistar rat skin as a membrane for 30 hours in vertical diffusion sel. The transport profiles were analyzed based on the lag time diffusion method. It is showed that oleic acid pretreatment did not effect on losartan permeation rate and efficiency of 2 mg/mL potassium losartan concentration. However, such pretreatment enhanced losartan permeation rate and efficiency 21 and 23-fold higher respectively for 10 mg/mL the potassium losartan concentration. It is predicted that losartan minimum effective plasma concentration can be achieved in transdermal administration through this transport improvement in normal application area.


Keywords: losartan; transdermal; oleic acid; in vivo prediction

Published at: Vol 6, No 1 (2019) pages: 21-27

DOI: 10.7454/psr.v6i1.4120


Access Counter: 1012 views

Full PDF Download

References:

Achuthan, S., Chung, B. J., Ghosh, P., Rangachari, V., & Vaidya, A. (2011). A modified Stokes-Einstein equation for Aβ aggregation. BMC Bioinformatics, 12(SUPPL. 10). https://doi.org/10.1186/1471-2105-12-S10-S13

Binarjo, A. (2014). Faktor Penentu permeasi transdermal:Tinjauan berdasarkan hukum fick I. Pharmaceutical Sciences and Research (PSR), 9(3), 121-135–135. https://doi.org/10.7454/psr.v9i3.3348.

Binarjo, A., Nugroho, A.K. (2013). The study on losartan concentration determination using spectrophotometric and hplc method, and its application to transdermal transport in vitro. Pharmaciana, 3(1), 31–48.

Bouwstra, J. A., G. S. Gooris, and M. Ponec. (2008). Skin lipid organization, composition and barrier function. International Journal of Cosmetic Science, 30(5), 388–388. https://doi.org/10.1111/j.1468-2494.2008.00430_1.x.

Choi, J. H., Shin, S., Park, D., Jeon, J. H., Choi, B. H., Jang, M. J., … Kim, Y. B. (2009). Comparative antihypertensive activities of losartan and hm70186 in rats with hepatic dysfunction. Archives of Pharmacal Research, 32(7), 1005–11. https://doi.org/10.1007/s12272-009-1705-0.

Dina, R., and Jafari, M. (2000). Angiotensin II-receptor antagonists: An overview. Am J Health Syst Pharm, 57, 231–41.

Haftek, M. (2014). Memory’ of the Stratum Corneum: Exploration of the Epidermis’ Past. British Journal of Dermatology, 171, 6–9. https://doi.org/10.1111/bjd.13243.

Koh, E. J., Yoon, S. J., & Lee, S. M. (2013). Losartan protects liver against ischaemia/reperfusion injury through PPAR-γ activation and receptor for advanced glycation end-products down-regulation. British Journal of Pharmacology, 169(6), 1404–1416. https://doi.org/10.1111/bph.12229.

Lacy, C.F., L.L. Armstrong, and N.B. Ingrim. (1998). Drug Information Handbook. 6th Ed. Cleveland: Lexi-Com Inc.

Lee, Craig R., John A. Pieper, Alan L. Hinderliter, Joyce A. Blaisdell, and Joyce A. Goldstein. (2003). Losartan and E3174 Pharmacokinetics in Cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 Individuals. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 23, 6, 720–25. https://doi.org/10.1592/phco.23.6.720.32187.

Martin, A, P Bustamante, and A.H.C. Chun. (1993). Physical pharmacy, physical chemical principles in The Pharmaceutical Sciences. 4th Ed. Philadelphia: Lea and Febiger.

Meloun, Milan, Tomáš Syrový, and Aleš Vrána. (2005). The thermodynamic dissociation constants of losartan, paracetamol, phenylephrine and quinine by the regression analysis of spectrophotometric data. Analytica Chimica Acta, 533, (1), 97–110. https://doi.org/10.1016/j.aca.2004.11.007.

Meshulam, Y., Kadar, T., Wengier, A., Dachir, S., and Levy, A. (1993). Transdermal penetration of physostigmine: effects of oleic acid enhancer. Drug Development Research, 28(4), 510–15. https://doi.org/10.1002/ddr.430280410.

Moghimi, H. R., N. Noorani, and A. Zarghi. (2010). Stereoselective permeation of tretinoin and isotretinoin through enhancer-treated rat skin. II. Effects of lipophilic penetration enhnacers. Iranian Journal of Pharmaceutical Research, 3(0), 17–22.

Murthy, T.E.G.K., Manogna K. Kommineni, and Candasamy Mayuren. (2013). Influence of losartan on the hypoglycemic activity of glimepiride in normal and diabetic rats. Therapeutic Advances in Endocrinology and Metabolism, 4(5), 133–38. https://doi.org/10.1177/2042018813509397.

Muth, J.E.D. (1999). Basic statistics and pharmaceutical statistical application. New York: Marcel Dekker Inc.

Naik, A, L.A.R.M Pechtold, and R.O Potts. (1995). Mechanism of oleic acid-induced skin penetration enhancement in vivo in humans. Journal of Controlled Release, 37(3), 299–306. https://doi.org/10.1016/0168-3659(95)00088-7.

Nakamura, A., Mori, D., & Tojo, K. (2012). Evaluation of the predicted time-concentration profile of serum tulobuterol in human after transdermal application. Chemical & Pharmaceutical Bulletin, 60(3), 300–305.

Pan, Y., Q. Y. Qiao, L. H. Pan, D. C. Zhou, C. Hu, H. F. Gu, S. K. Fu, X. L. Liu, and H. M. Jin. (2015). Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Association, 123(3), 170–77. https://doi.org/10.1055/s-0034-1395658.

Park, Eun-Seok, Yu Cui, Bum-Jin Yun, In-Ja Ko, and Sang-Cheol Chi. (2005). Transdermal delivery of piroxicam using microemulsions. Archives of Pharmacal Research, 28(2), 243–48.

Paudel, Kalpana S, Mikolaj Milewski, Courtney L Swadley, Nicole K Brogden, Priyanka Ghosh, and Audra L Stinchcomb. (2010). Challenges and Opportunities in Dermal/Transdermal Delivery. Therapeutic Delivery 1 (1): 109–31.

Petkar, K.C, and S.B Kuchekar. (2007). In-Vitro Percutaneous Absorption of Losartan Potassium in Human Skin and Prediction of Human Skin Permeability. DARU Journal of Pharmaceutical Sciences 15 (2): 53–60.

Ripley, Elizabeth, and Ari Hirsch. (2010). Fifteen Years of Losartan: What Have We Learned about Losartan That Can Benefit Chronic Kidney Disease Patients? International Journal of Nephrology and Renovascular Disease 3 (June): 93–98.

Soldner, Andrea, Leslie Z Benet, Ernst Mutschler, and Uwe Christians. (2000). Active Transport of the Angiotensin-II Antagonist Losartan and Its Main Metabolite EXP 3174 across MDCK-MDR1 and Caco-2 Cell Monolayers. British Journal of Pharmacology 129 (6): 1235–43. https://doi.org/10.1038/sj.bjp.0703150.

Tanner, T., and R. Marks. (2008). Delivering Drugs by the Transdermal Route: Review and Comment. Skin Research and Technology: Official Journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) 14 (3): 249–60. https://doi.org/10.1111/j.1600-0846.2008.00316.x.

Thakur, Reena, Md Khalid Anwer, Mohammad S. Shams, Asgar Ali, Roop K. Khar, Faiyaz Shakeel, and Ehab I. Taha. (2009). Proniosomal Transdermal Therapeutic System of Losartan Potassium: Development and Pharmacokinetic Evaluation. Journal of Drug Targeting 17 (6): 442–49. https://doi.org/10.1080/10611860902963039.

Vashisth, Indu, Abdul Ahad, Mohd. Aqil, and Suraj P. Agarwal. (2014). Investigating the Potential of Essential Oils as Penetration Enhancer for Transdermal Losartan Delivery: Effectiveness and Mechanism of Action. Asian Journal of Pharmaceutical Sciences 9 (5): 260–67. https://doi.org/10.1016/j.ajps.2014.06.007.

Wester, Ronald C., and Howard I. Maibach. (1976). Relationship of Topical Dose and Percutaneous Absorption in Rhesus Monkey and Man. Journal of Investigative Dermatology 67 (4): 518–20. https://doi.org/10.1111/1523-1747.ep12664543.